US Patent Issued to Veracyte SD on Dec. 16 for "Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy" (Canadian, American Inventors)

ALEXANDRIA, Va., Dec. 16 -- United States Patent no. 12,497,660, issued on Dec. 16, was assigned to Veracyte SD Inc. (San Diego).

"Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy" was invented by Elai Davicioni (La Jolla, Calif.), Nicholas George Erho (Vancouver, Canada), Jonathan Lehrer (Vancouver, Canada), Felix Y. Feng (Hillsborough, Calif.) and Shuang G. Zhao (Ann Arbor, Mich.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods, systems, and kits for the diagnosis, prognosis and the determination of cancer progression of prostate cancer in a subject are disclosed. In particular, the disclosure relates to the use of immu...